Baudax Bio

company

About

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$5M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
nasdaq:BXRX

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
9
$114.30M
Baudax Bio has raised a total of $114.30M in funding over 2 rounds. Their latest funding was raised on Dec 2, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 2, 2022 Post-IPO Equity $5M Detail
Aug 29, 2022 Post-IPO Equity $6.20M Detail
May 17, 2022 Post-IPO Equity $2M Detail
Feb 24, 2022 Post-IPO Equity $10M Detail
Dec 28, 2021 Post-IPO Equity $4.20M Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Baudax Bio is funded by 1 investors. Marathon Asset Management are the most recent investors.
Investor Name Lead Investor Funding Round
Marathon Asset Management Yes Post-IPO Debt

Employee Profiles

Number of Employee Profiles
3
Baudax Bio has 3 current employee profiles, including Executive Gerri Henwood
Executive
Executive
Executive